Showcasing the NObreath® and Smokerlyzer® range while connecting with research teams and global distribution partners at Europe’s leading respiratory congress.
Bedfont® Scientific Limited, a world leader in breath analysis, is excited to be attending this year’s European Respiratory Society (ERS) Congress in Barcelona. With over 50 years of experience in the design and manufacture of medical breath analysis devices, Bedfont® looks to connect with professionals in healthcare and clinical research to share its innovative Fractional exhaled Nitric Oxide (FeNO) and carbon monoxide (CO) monitoring technology.
The ERS Congress is the world’s largest international meeting dedicated to respiratory medicine, bringing together approximately 20,000 clinicians, researchers, healthcare professionals and industry leaders from across the world. This year’s congress takes place in Barcelona from the 5th to the 9th of September, providing a platform for sharing the latest scientific advances, promoting collaboration and driving innovation in respiratory care.
This year’s theme is “United for better breathing: partnership between patients, clinicians and researchers.” With Bedfont® looking to strengthen its commitment to respiratory clinical research, ERS provides the perfect platform to connect with industry professionals and showcase its innovations.
Jason Smith, CEO at Bedfont®, comments, “ERS Congress is one of the most important events in the respiratory calendar, bringing together the very people driving innovation in respiratory medicine. We’re excited to return to Barcelona to showcase our NObreath® FeNO device and Smokerlyzer® range, while strengthening relationships with our distributor network and connecting with research teams and healthcare professionals. As Bedfont® continues to expand its presence in medical research, we’re looking forward to discussing how our trusted respiratory monitoring solutions can further support studies and ultimately improve patient care around the world.”
The Bedfont® team will be at Stand R.19 from the 6th to the 9th of September, where visitors can explore the NObreath® and Smokerlyzer® devices and meet the experts behind them. Joining the team is renowned respiratory nurse and clinical leader, Carol Stonham MBE, who will be on the stand to share her expertise and provide valuable clinical insight into the role of FeNO testing in respiratory care. Carol will be available alongside Bedfont’s Clinical Research Partnerships Manager, Hannah Vince-Drew, to answer questions and discuss the application of FeNO testing in both clinical practice and clinical research.
To learn more, visit the website here.
